Who’s winning the race to treat NASH?
(HYACINTH EMPINADO/STAT)
NASH, a pervasive and currently untreatable liver disease, has set in motion a drug industry gold rush, with scores of companies angling to claim the lion’s share of what’s thought to become a multibillion-dollar market. But, science being science, treating the disease has turned out to be more complicated than researchers once thought, and keeping up on who’s up and who’s down in NASH has become a complicated endeavor.
That’s why STAT’s Adam Feuerstein came up with cheat sheet on the biggest players in space. We’re just days removed from Europe’s big scientific conference on liver disease, which makes it an ideal time to take stock of a frontrunner losing luster, an up-and-comer on the spin, and a promising idea still subject to avid debate.
Read more.
That’s why STAT’s Adam Feuerstein came up with cheat sheet on the biggest players in space. We’re just days removed from Europe’s big scientific conference on liver disease, which makes it an ideal time to take stock of a frontrunner losing luster, an up-and-comer on the spin, and a promising idea still subject to avid debate.
Read more.
.png)
No hay comentarios:
Publicar un comentario